{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:58:00Z","timestamp":1792277880764,"version":"4.4.0"},"reference-count":229,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFF1201300"],"award-info":[{"award-number":["2021YFF1201300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273402"],"award-info":[{"award-number":["82273402"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92374114"],"award-info":[{"award-number":["92374114"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81930065"],"award-info":[{"award-number":["81930065"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Program of Guangdong","doi-asserted-by":"publisher","award":["2019B020227002"],"award-info":[{"award-number":["2019B020227002"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2014A030312015"],"award-info":[{"award-number":["2014A030312015"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Science and Technology Program of Guangzhou City","doi-asserted-by":"publisher","award":["202002030208"],"award-info":[{"award-number":["202002030208"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Science and Technology Program of Guangzhou City","doi-asserted-by":"publisher","award":["201904020046"],"award-info":[{"award-number":["201904020046"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Science and Technology Program of Guangzhou City","doi-asserted-by":"publisher","award":["2019B020227002"],"award-info":[{"award-number":["2019B020227002"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangzhou Key Research and Development Project","award":["202206080008"],"award-info":[{"award-number":["202206080008"]}]},{"DOI":"10.13039\/501100018601","name":"Guangdong Special Support Plan","doi-asserted-by":"publisher","award":["2023TX07Y430"],"award-info":[{"award-number":["2023TX07Y430"]}],"id":[{"id":"10.13039\/501100018601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Gastric cancer is a malignant tumor that ranks third in cancer-related deaths worldwide. Early-stage gastric cancer can often be effectively managed through surgical resection. However, the majority of cases are diagnosed in advanced stages, where outcomes with conventional radiotherapy and chemotherapy remain unsatisfactory. Immunotherapy offers a novel approach to treating molecularly heterogeneous gastric cancer by modifying the immunosuppressive tumor microenvironment. Immune checkpoint inhibitors and adoptive cell therapy are regarded as promising modalities in cancer immunotherapy. Food and Drug Administration-approved programmed death-receptor inhibitors, such as pembrolizumab, in combination with chemotherapy, have significantly extended overall survival in gastric cancer patients and is recommended as a first-line treatment. Despite challenges in solid tumor applications, adoptive cell therapy has demonstrated efficacy against various targets in gastric cancer treatment. Among these approaches, chimeric antigen receptor-T cell therapy research is the most widely explored and chimeric antigen receptor-T cell therapy targeting claudin18.2 has shown acceptable safety and robust anti-tumor capabilities. However, these advancements primarily remain in preclinical stages and further investigation should be made to promote their clinical application. This review summarizes the latest research on immune checkpoint inhibitors and adoptive cell therapy and their limitations, as well as the role of nanoparticles in enhancing immunotherapy.<\/jats:p>","DOI":"10.1093\/pcmedi\/pbae020","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T06:47:18Z","timestamp":1726728438000},"source":"Crossref","is-referenced-by-count":17,"title":["Novel immunotherapeutic approaches in gastric cancer"],"prefix":"10.1093","volume":"7","author":[{"given":"Meng","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["China"]},{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences , Guangzhou 510060 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuhao","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Molecular Diagnostics, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["China"]},{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences , Guangzhou 510060 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1655-6762","authenticated-orcid":false,"given":"Alessandro","family":"Mannucci","sequence":"additional","affiliation":[{"name":"Gastroenterology and Gastrointestinal Emndoscopy Unit, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University , Milan 20132 ,","place":["Italy"]},{"name":"Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope ; Monrovia, CA 91016 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060 ,","place":["China"]},{"name":"Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences , Guangzhou 510060 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"2024122016182282300_bib1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2024122016182282300_bib2","doi-asserted-by":"publisher","first-page":"23142","DOI":"10.1038\/s41598-021-02391-z","article-title":"Survival outcomes of management in metastatic gastric adenocarcinoma patients","volume-title":"Sci Rep","author":"Hu","year":"2021"},{"key":"2024122016182282300_bib3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000473881","article-title":"Heterogeneity in gastric cancer: from pure morphology to molecular classifications","volume":"85","author":"Gullo","year":"2018","journal-title":"Pathobiology"},{"key":"2024122016182282300_bib4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume-title":"Nature","author":"Cancer Genome Atlas Research N","year":"2014"},{"key":"2024122016182282300_bib5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3390\/v15010176","article-title":"Tumor-infiltrating T cells in EBV-associated gastric carcinomas exhibit high levels of multiple markers of activation, effector gene expression, and exhaustion","volume-title":"Viruses","author":"Salnikov","year":"2023"},{"key":"2024122016182282300_bib6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41392-023-01622-1","article-title":"Dynamic single-cell mapping unveils Epstein\u2012Barr virus-imprinted T-cell exhaustion and on-treatment response","volume-title":"Signal Transduct Target Ther","author":"Qiu","year":"2023"},{"key":"2024122016182282300_bib7","doi-asserted-by":"publisher","first-page":"1938381","DOI":"10.1080\/2162402X.2021.1938381","article-title":"The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer","volume":"10","author":"Wei","year":"2021","journal-title":"Oncoimmunology"},{"key":"2024122016182282300_bib8","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume-title":"Nat Med","author":"Kim","year":"2018"},{"key":"2024122016182282300_bib9","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability As a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024122016182282300_bib10","doi-asserted-by":"publisher","first-page":"e007104","DOI":"10.1136\/jitc-2023-007104","article-title":"Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade","volume":"11","author":"Randon","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2024122016182282300_bib11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.21037\/pcm-22-48","article-title":"Microsatellite instability and immunotherapy in gastric cancer: a narrative review","volume":"6","author":"Duan","year":"2023","journal-title":"Precis Cancer Med"},{"key":"2024122016182282300_bib12","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.3390\/jcm12072636","article-title":"Updated immunotherapy for gastric cancer","volume":"12","author":"Narita","year":"2023","journal-title":"J Clin Med"},{"key":"2024122016182282300_bib13","author":"Janjigian"},{"key":"2024122016182282300_bib14","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1158\/2159-8290.CD-21-0219","article-title":"Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer","volume-title":"Cancer Discov","author":"Kwon","year":"2021"},{"key":"2024122016182282300_bib15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.humpath.2013.09.004","article-title":"Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers","volume":"45","author":"Kim","year":"2014","journal-title":"Hum Pathol"},{"key":"2024122016182282300_bib16","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.3390\/cells12232712","article-title":"Chromosomal instability-driven cancer progression: interplay with the tumour microenvironment and therapeutic strategies","volume-title":"Cells","author":"Zheng","year":"2023"},{"key":"2024122016182282300_bib17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","article-title":"Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development","volume-title":"Trends Cancer","author":"Yasuda","year":"2024"},{"key":"2024122016182282300_bib18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.neo.2017.02.012","article-title":"Chromosomal instability in gastric cancer biology","volume":"19","author":"Maleki","year":"2017","journal-title":"Neoplasia"},{"key":"2024122016182282300_bib19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.annonc.2020.04.011","article-title":"Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas","volume":"31","author":"Derks","year":"2020","journal-title":"Ann Oncol"},{"key":"2024122016182282300_bib20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s13238-020-00813-8","article-title":"Unexpected guests in the tumor microenvironment: microbiome in cancer","volume":"12","author":"Wong-Rolle","year":"2021","journal-title":"Protein Cell"},{"key":"2024122016182282300_bib21","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1002\/mef2.65","article-title":"High sucralose intake suppresses autoimmunity and promotes tumor growth by limiting T cell-mediated immune responses","volume-title":"MedComm\u2014Future Medicine","author":"Lin","year":"2023"},{"key":"2024122016182282300_bib22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medicina56010015","article-title":"Tumor microenvironment","volume-title":"Medicina (Kaunas)","author":"Arneth","year":"2019"},{"key":"2024122016182282300_bib23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2741\/3613","article-title":"Cancer associated fibroblasts (CAFs) in tumor microenvironment","volume-title":"Front Biosci (Landmark Ed)","author":"Xing","year":"2010"},{"key":"2024122016182282300_bib24","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.3390\/cancers13051172","article-title":"Cancer-associated fibroblast-induced resistance to chemotherapy and radiotherapy in gastrointestinal cancers","volume-title":"Cancers (Basel)","author":"Ham","year":"2021"},{"key":"2024122016182282300_bib25","doi-asserted-by":"publisher","first-page":"13482","DOI":"10.3390\/ijms241713482","article-title":"Cancer-associated fibroblast heterogeneity and its influence on the extracellular matrix and the tumor microenvironment","volume":"24","author":"Knipper","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2024122016182282300_bib26","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ccell.2023.06.005","article-title":"Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression","volume-title":"Cancer Cell","author":"Wang","year":"2023"},{"key":"2024122016182282300_bib27","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/0008-5472.CAN-20-2756","article-title":"Cancer-associated fibroblasts promote aggressive gastric Cancer phenotypes via Heat Shock factor 1-mediated secretion of extracellular vesicles","volume":"81","author":"Grunberg","year":"2021","journal-title":"Cancer Res"},{"key":"2024122016182282300_bib28","doi-asserted-by":"publisher","first-page":"e1481","DOI":"10.1002\/ctm2.1481","article-title":"H. pylori-induced NF-\u03bab-PIEZO1-YAP1-CTGF axis drives gastric cancer progression and cancer-associated fibroblast-mediated tumour microenvironment remodelling","volume-title":"Clin Transl Med","author":"Chen","year":"2023"},{"key":"2024122016182282300_bib29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41420-023-01336-x","article-title":"Cancer-associated fibroblast-secreted IGFBP7 promotes gastric cancer by enhancing tumor associated macrophage infiltration via FGF2\/FGFR1\/PI3K\/AKT axis","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov"},{"key":"2024122016182282300_bib30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10120-017-0760-3","article-title":"Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma","volume-title":"Gastric Cancer","author":"Harada","year":"2018"},{"key":"2024122016182282300_bib31","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s10120-015-0579-8","article-title":"Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination","volume-title":"Gastric Cancer","author":"Yamaguchi","year":"2016"},{"key":"2024122016182282300_bib32","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.4049\/jimmunol.181.6.3733","article-title":"Macrophage polarization in bacterial infections","volume":"181","author":"Benoit","year":"2008","journal-title":"J Immunol"},{"key":"2024122016182282300_bib33","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1073\/pnas.0400983101","article-title":"Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria","volume":"101","author":"Verreck","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024122016182282300_bib34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-023-03601-5","article-title":"CD204-positive M2-like tumor-associated macrophages increase migration of gastric cancer cells by upregulating miR-210 to reduce NTN4 expression","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2024122016182282300_bib35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.21147\/j.issn.1000-9604.2020.01.09","article-title":"Tumor-associated macrophages regulate gastric cancer cell invasion and metastasis through TGF\u03b22\/NF-\u03baB\/Kindlin-2 axis","volume":"32","author":"Wang","year":"2020","journal-title":"Chin J Cancer Res"},{"key":"2024122016182282300_bib36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12957-024-03353-1","article-title":"Involvement of CX3CR1(+) cells appearing in the abdominal cavity in the immunosuppressive environment immediately after gastric cancer surgery","volume":"22","author":"Natsuki","year":"2024","journal-title":"World J Surg Oncol"},{"key":"2024122016182282300_bib37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-3-030-91311-3_3","article-title":"Tumor-infiltrating lymphocytes and their role in solid Tumor progression","volume-title":"Exp Suppl","author":"Whiteside","year":"2022"},{"key":"2024122016182282300_bib38","doi-asserted-by":"publisher","first-page":"9007","DOI":"10.1007\/s00432-023-04823-x","article-title":"CD4(-)\/CD8(-) double-negative tumor-infiltrating lymphocytes expanded from solid tumor tissue suppress the proliferation of tumor cells in an MHC-independent way","volume":"149","author":"Lu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2024122016182282300_bib39","doi-asserted-by":"publisher","first-page":"e008355","DOI":"10.1136\/jitc-2023-008355","article-title":"Multiomics profiling reveals the benefits of gamma-delta (\u03b3\u03b4) T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer","volume":"12","author":"Li","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2024122016182282300_bib40","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.intimp.2019.05.009","article-title":"Recent advances in the study of regulatory T cells in gastric cancer","volume":"73","author":"Liu","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"2024122016182282300_bib41","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume-title":"Signal Transduct Target Ther","author":"Li","year":"2021"},{"key":"2024122016182282300_bib42","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s10120-023-01456-4","article-title":"Tumor-infiltrating monocytic myeloid-derived suppressor cells contribute to the development of an immunosuppressive tumor microenvironment in gastric cancer","volume-title":"Gastric Cancer","author":"Tsutsumi","year":"2024"},{"key":"2024122016182282300_bib43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3892\/ol.2024.14270","article-title":"Roles of endothelial cell specific molecule\u20131 in tumor angiogenesis (Review)","volume":"27","author":"Zhou","year":"2024","journal-title":"Oncol Lett"},{"key":"2024122016182282300_bib44","doi-asserted-by":"publisher","first-page":"2108368","DOI":"10.1155\/2022\/2108368","article-title":"Platelet-derived growth factors affect clinical features and prognosis of gastric cancer","volume":"2022","author":"Zhao","year":"2022","journal-title":"J Oncol"},{"key":"2024122016182282300_bib45","doi-asserted-by":"publisher","first-page":"11940","DOI":"10.18632\/aging.205158","article-title":"Integrated analysis of single-cell and bulk RNA-sequencing data reveals the prognostic value and molecular function of THSD7A in gastric cancer","volume":"15","author":"Shen","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"2024122016182282300_bib46","doi-asserted-by":"publisher","first-page":"19375","DOI":"10.18632\/aging.203334","article-title":"THBS4\/integrin \u03b12 axis mediates BM-MSCs to promote angiogenesis in gastric cancer associated with chronic Helicobacter pylori infection","volume-title":"Aging (Albany NY)","author":"He","year":"2021"},{"key":"2024122016182282300_bib47","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s12015-024-10720-8","article-title":"Gastric cancer mesenchymal stem cells trigger endothelial cell functional changes to promote cancer progression","volume":"20","author":"Cui","year":"2024","journal-title":"Stem Cell Rev and Rep"},{"key":"2024122016182282300_bib48","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"2024122016182282300_bib49","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/s1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"2024122016182282300_bib50","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/jco.22.02331","article-title":"Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline","volume":"41","author":"Shah","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024122016182282300_bib51","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/jco.23.00975","article-title":"Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"key":"2024122016182282300_bib52","doi-asserted-by":"publisher","first-page":"1198365","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"2024122016182282300_bib53","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41571-024-00897-9","article-title":"From AACR 2024","volume":"21","author":"Romero","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2024122016182282300_bib54","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1158\/1538-7445.AM2018-2776","article-title":"MEDI5752: A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells","volume":"78","author":"Dovedi","year":"2018","journal-title":"Cancer Res"},{"key":"2024122016182282300_bib55","doi-asserted-by":"publisher","first-page":"785091","DOI":"10.3389\/fimmu.2021.785091","article-title":"Immune checkpoint LAG3 and its Ligand FGL1 in cancer","volume":"12","author":"Shi","year":"2021","journal-title":"Front Immunol"},{"key":"2024122016182282300_bib56","doi-asserted-by":"publisher","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric antigen receptors modified T-cells for cancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2024122016182282300_bib57","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-Human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024122016182282300_bib58","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024122016182282300_bib59","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2024122016182282300_bib60","doi-asserted-by":"publisher","first-page":"e002723","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2024122016182282300_bib61","doi-asserted-by":"publisher","first-page":"121459","DOI":"10.1016\/j.lfs.2023.121459","article-title":"Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach","volume-title":"Life Sci","author":"Entezam","year":"2023"},{"key":"2024122016182282300_bib62","doi-asserted-by":"publisher","first-page":"2002628","DOI":"10.1002\/advs.202002628","article-title":"The CAR T-cell mechanoimmunology at a glance","volume":"7","author":"Li","year":"2020","journal-title":"Adv Sci (Weinh)"},{"key":"2024122016182282300_bib63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.addr.2019.04.006","article-title":"CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs","volume-title":"Adv Drug Deliv Rev","author":"Rahbarizadeh","year":"2019"},{"key":"2024122016182282300_bib64","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.3389\/fimmu.2018.03180","article-title":"Lymphocytes in Cellular therapy: functional regulation of CAR T cells","volume":"9","author":"Dwivedi","year":"2018","journal-title":"Front Immunol"},{"key":"2024122016182282300_bib65","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with Human variable regions is affected by hinge and transmembrane domains","volume-title":"Mol Ther","author":"Alabanza","year":"2017"},{"key":"2024122016182282300_bib66","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"2024122016182282300_bib67","doi-asserted-by":"publisher","first-page":"e1373","DOI":"10.1002\/cti2.1373","article-title":"Allogeneic CD20-targeted gammadelta T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models","volume":"11","author":"Nishimoto","year":"2022","journal-title":"Clin Transl Immunology"},{"key":"2024122016182282300_bib68","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front Immunol"},{"key":"2024122016182282300_bib69","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4049\/jimmunol.182.1.164","article-title":"Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo","volume":"182","author":"van\u00a0der\u00a0Veken","year":"2009","journal-title":"J Immunol"},{"key":"2024122016182282300_bib70","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024122016182282300_bib71","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume-title":"Leukemia","author":"Imai","year":"2004"},{"key":"2024122016182282300_bib72","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"2024122016182282300_bib73","first-page":"4133","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"2024122016182282300_bib74","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.3748\/wjg.v22.i26.5879","article-title":"HER2 heterogeneity in gastric\/gastroesophageal cancers: from benchside to practice","volume":"22","author":"Grillo","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2024122016182282300_bib75","doi-asserted-by":"publisher","first-page":"20502","DOI":"10.1038\/srep20502","article-title":"Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition","volume-title":"Sci Rep","author":"Huang","year":"2016"},{"key":"2024122016182282300_bib76","doi-asserted-by":"publisher","first-page":"11634","DOI":"10.1038\/srep11634","article-title":"Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance","volume-title":"Sci Rep","author":"Zuo","year":"2015"},{"key":"2024122016182282300_bib77","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.2147\/jir.S368138","article-title":"From Anti-HER-2 to Anti-HER-2-CAR-T cells: an evolutionary immunotherapy approach for gastric cancer. Review","volume-title":"Journal of Inflammation Research","author":"Sun","year":"2022"},{"key":"2024122016182282300_bib78","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13238-017-0384-8","article-title":"Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo","volume-title":"Protein Cell","author":"Song","year":"2018"},{"key":"2024122016182282300_bib79","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13238-017-0384-8","article-title":"Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitroand xenotransplanted tumors in vivo. Article","volume-title":"Protein & Cell","author":"Song","year":"2018"},{"key":"2024122016182282300_bib80","first-page":"106","article-title":"Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. Article","volume-title":"American Journal of Cancer Research","author":"Han","year":"2018"},{"key":"2024122016182282300_bib81","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy","volume":"10","author":"Cao","year":"2022","journal-title":"Biomark Res"},{"key":"2024122016182282300_bib82","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"2024122016182282300_bib83","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/jnci\/djy134","article-title":"Claudin18.2-Specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer.\u00a0","volume-title":"JNCI-Journal of the National Cancer Institute","author":"Jiang","year":"2019"},{"key":"2024122016182282300_bib84","doi-asserted-by":"publisher","first-page":"e007927","DOI":"10.1136\/jitc-2023-007927","article-title":"Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells.\u00a0","volume-title":"J Immunother Cancer","author":"Botta","year":"2024"},{"key":"2024122016182282300_bib85","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume-title":"Nat Med","author":"Qi","year":"2022"},{"key":"2024122016182282300_bib86","doi-asserted-by":"publisher","first-page":"140","DOI":"10.5230\/jgc.2012.12.3.140","article-title":"Expression of intercellular adhesion molecule-1 and e-selectin in gastric cancer and their clinical significance","volume":"12","author":"Jung","year":"2012","journal-title":"Journal of Gastric Cancer"},{"key":"2024122016182282300_bib87","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.omto.2020.08.009","article-title":"Chimeric antigen receptor T cell therapy targeting ICAM-1 in gastric cancer","volume":"18","author":"Jung","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"2024122016182282300_bib88","doi-asserted-by":"publisher","first-page":"14366","DOI":"10.1038\/s41598-017-14749-3","article-title":"Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity","volume-title":"Sci Rep","author":"Park","year":"2017"},{"key":"2024122016182282300_bib89","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/2326-6066.CIR-21-0062","article-title":"Bispecific CAR T cells against EpCAM and inducible ICAM-1 overcome antigen heterogeneity and generate superior antitumor responses","volume":"9","author":"Yang","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"2024122016182282300_bib90","doi-asserted-by":"publisher","first-page":"e7481","DOI":"10.1097\/MD.0000000000007481","article-title":"Correlations of ICAM-1 gene polymorphisms with susceptibility and multidrug resistance in colorectal cancer in a Chinese population","volume-title":"Medicine (Baltimore)","author":"Liu","year":"2017"},{"key":"2024122016182282300_bib91","doi-asserted-by":"publisher","first-page":"e0124151","DOI":"10.1371\/journal.pone.0124151","article-title":"The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients","volume":"10","author":"Deng","year":"2015","journal-title":"PLoS One"},{"key":"2024122016182282300_bib92","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.3892\/ol.2019.10935","article-title":"Use of immunotherapy in the treatment of gastric cancer","volume":"18","author":"Yang","year":"2019","journal-title":"Oncol Lett"},{"key":"2024122016182282300_bib93","doi-asserted-by":"publisher","first-page":"1182409","DOI":"10.3389\/fimmu.2023.1182409","article-title":"Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"2024122016182282300_bib94","doi-asserted-by":"publisher","first-page":"1899469","DOI":"10.1080\/2162402X.2021.1899469","article-title":"Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine","volume-title":"Oncoimmunology","author":"Cha","year":"2021"},{"key":"2024122016182282300_bib95","doi-asserted-by":"publisher","first-page":"947648","DOI":"10.3389\/fimmu.2022.947648","article-title":"Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications","volume":"13","author":"Silveira","year":"2022","journal-title":"Front Immunol"},{"key":"2024122016182282300_bib96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2004.09.044","article-title":"c-met as a target for human cancer and characterization of inhibitors for therapeutic intervention","volume":"225","author":"Christensen","year":"2005","journal-title":"Cancer Lett"},{"key":"2024122016182282300_bib97","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Vande Woude GF. Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2024122016182282300_bib98","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.3390\/cancers13225738","article-title":"c-met-specific chimeric antigen receptor T cells demonstrate anti-tumor effect in c-met positive gastric cancer","volume-title":"Cancers","author":"Kang","year":"2021"},{"key":"2024122016182282300_bib99","doi-asserted-by":"publisher","first-page":"1901434","DOI":"10.1080\/2162402x.2021.1901434","article-title":"Construction of PD1\/CD28 chimeric-switch receptor enhances anti-tumor ability of c-met CAR-T in gastric cancer.\u00a0","volume-title":"Oncoimmunology","author":"Chen","year":"2021"},{"key":"2024122016182282300_bib100","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s10637-020-00978-3","article-title":"Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors. Article","volume-title":"Invest New Drugs","author":"Yuan","year":"2021"},{"key":"2024122016182282300_bib101","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1158\/1538-7445.Am2023-1772","article-title":"Development of a novel L1CAM-targeted CAR-T, CX804, and its therapeutic efficacy in ovarian and gastric cancer. Meeting abstract","volume-title":"Cancer Res","author":"Che","year":"2023"},{"key":"2024122016182282300_bib102","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00432-009-0569-5","article-title":"EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer","volume":"135","author":"Wenqi","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"2024122016182282300_bib103","doi-asserted-by":"publisher","first-page":"S880","DOI":"10.1016\/j.annonc.2022.07.863","article-title":"EpCAM-targeted CAR-T cell therapy in patients with advanced colorectal and gastric cancers. Meeting Abstract","volume-title":"Ann Oncol","author":"Fang","year":"2022"},{"key":"2024122016182282300_bib104","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1007\/s00262-021-02891-x","article-title":"Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy","volume-title":"Cancer Immunology Immunotherapy","author":"Han","year":"2021"},{"key":"2024122016182282300_bib105","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s43018-022-00344-7","article-title":"Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues","volume-title":"Nat Cancer","author":"Feng","year":"2022"},{"key":"2024122016182282300_bib106","doi-asserted-by":"publisher","first-page":"e0266980","DOI":"10.1371\/journal.pone.0266980","article-title":"BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity","volume-title":"PLoS One","author":"Hickman","year":"2022"},{"key":"2024122016182282300_bib107","doi-asserted-by":"publisher","first-page":"e0198347","DOI":"10.1371\/journal.pone.0198347","article-title":"Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer","volume-title":"PLoS One","author":"Kim","year":"2018"},{"key":"2024122016182282300_bib108","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-019-0704-y","article-title":"Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer","volume":"12","author":"Lv","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2024122016182282300_bib109","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40364-020-00198-0","article-title":"Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth","volume":"8","author":"Qin","year":"2020","journal-title":"Biomark Res"},{"key":"2024122016182282300_bib110","first-page":"79","article-title":"MUC1-Tn-targeting chimeric antigen receptor-modified V\u03b39V\u03b42 T cells with enhanced antigen-specific anti-tumor activity","volume":"11","author":"Zhai","year":"2021","journal-title":"Am J Cancer Res"},{"key":"2024122016182282300_bib111","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s43018-022-00344-7","article-title":"Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues","volume-title":"Nat Cancer","author":"Feng","year":"2022"},{"key":"2024122016182282300_bib112","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12935-022-02471-8","article-title":"Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells","volume-title":"Cancer Cell Int","author":"Sun","year":"2022"},{"key":"2024122016182282300_bib113","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s00262-019-02392-y","article-title":"ANTXR1 (TEM8) overexpression in gastric adenocarcinoma makes the protein a potential target of immunotherapy","volume-title":"Cancer Immunology Immunotherapy","author":"Sotoudeh","year":"2019"},{"key":"2024122016182282300_bib114","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40364-020-0183-x","article-title":"PSCA is a target of chimeric antigen receptor T cells in gastric cancer","volume-title":"Biomark Res","author":"Wu","year":"2020"},{"key":"2024122016182282300_bib115","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41422-022-00627-9","article-title":"Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response","volume":"32","author":"He","year":"2022","journal-title":"Cell Res"},{"key":"2024122016182282300_bib116","doi-asserted-by":"publisher","first-page":"835762","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects","volume-title":"Front Immunol","author":"Shafer","year":"2022"},{"key":"2024122016182282300_bib117","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","article-title":"Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains","volume":"200","author":"Harris","year":"2018","journal-title":"J Immunol"},{"key":"2024122016182282300_bib118","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0959-440x(97)80156-x","article-title":"T-cell receptor structure and TCR complexes","volume":"7","author":"Wilson","year":"1997","journal-title":"Curr Opin Struct Biol"},{"key":"2024122016182282300_bib119","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nri2887","article-title":"Mechanisms for T cell receptor triggering","volume":"11","author":"van\u00a0der\u00a0Merwe","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"2024122016182282300_bib120","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.4049\/jimmunol.1501657","article-title":"Landscape of tumor antigens in T cell immunotherapy","volume":"195","author":"Ilyas","year":"2015","journal-title":"J Immunol"},{"key":"2024122016182282300_bib121","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s40425-019-0678-x","article-title":"Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1.\u00a0","volume-title":"J Immunother Cancer","author":"Marcinkowski","year":"2019"},{"key":"2024122016182282300_bib122","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"2024122016182282300_bib123","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.coi.2015.02.005","article-title":"Targeting cancer-specific mutations by T cell receptor gene therapy","volume":"33","author":"Blankenstein","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"2024122016182282300_bib124","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40364-023-00534-0","article-title":"Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges","volume":"11","author":"Pang","year":"2023","journal-title":"Biomark Res"},{"key":"2024122016182282300_bib125","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2024122016182282300_bib126","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5493\/wjem.v5.i2.84","article-title":"Role of the Wnt\/beta-catenin pathway in gastric cancer: an in-depth literature review","volume":"5","author":"Chiurillo","year":"2015","journal-title":"World J Exp Med"},{"key":"2024122016182282300_bib127","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024122016182282300_bib128","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.critrevonc.2016.11.016","article-title":"Tumor infiltrating lymphocytes in gastrointestinal tumors: controversies and future clinical implications","volume":"110","author":"Solinas","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2024122016182282300_bib129","doi-asserted-by":"publisher","first-page":"e003499","DOI":"10.1136\/jitc-2021-003499","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types","volume":"9","author":"Kverneland","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2024122016182282300_bib130","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.omto.2022.01.004","article-title":"Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy","volume-title":"Mol Ther Oncolytics","author":"Chamberlain","year":"2022"},{"key":"2024122016182282300_bib131","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","article-title":"Natural killer cells and other innate lymphoid cells in cancer","volume":"18","author":"Chiossone","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2024122016182282300_bib132","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/jcm8101702","article-title":"NK cell-based immunotherapy for hematological malignancies","volume":"8","author":"Sivori","year":"2019","journal-title":"J Clin Med"},{"key":"2024122016182282300_bib133","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/JLB.MR0618-224RR","article-title":"From the \u201cmissing self\u201d hypothesis to adaptive NK cells: insights of NK cell-mediated effector functions in immune surveillance","volume":"105","author":"Cruz-Mu\u00f1oz","year":"2019","journal-title":"J Leukocyte Biol"},{"key":"2024122016182282300_bib134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/6248590","article-title":"Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer","volume":"2018","author":"Han","year":"2018","journal-title":"J Immunol Res"},{"key":"2024122016182282300_bib135","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"2024122016182282300_bib136","doi-asserted-by":"publisher","first-page":"e1274","DOI":"10.1002\/cti2.1274","article-title":"CAR-NK cells: the next wave of cellular therapy for cancer","volume":"10","author":"Daher","year":"2021","journal-title":"Clin Transl Immunology"},{"key":"2024122016182282300_bib137","doi-asserted-by":"publisher","first-page":"732135","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \u201coff-the -shelf\u201d allogeneic NK and CAR-NK cell therapies","volume-title":"Front Immunol","author":"Heipertz","year":"2021"},{"key":"2024122016182282300_bib138","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1182\/bloodadvances.2019000835","article-title":"A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation","volume-title":"Blood Adv","author":"Li","year":"2019"},{"key":"2024122016182282300_bib139","doi-asserted-by":"publisher","first-page":"eaaz5618","DOI":"10.1126\/scitranslmed.aaz5618","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti\u2013PD-1 therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci Transl Med"},{"key":"2024122016182282300_bib140","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"2024122016182282300_bib141","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/cancers14040978","article-title":"Controlling cell trafficking: addressing failures in CAR T and NK cell therapy of solid tumours","volume-title":"Cancers (Basel)","author":"White","year":"2022"},{"key":"2024122016182282300_bib142","doi-asserted-by":"publisher","first-page":"953849","DOI":"10.3389\/fimmu.2022.953849","article-title":"Overcoming tumor resistance mechanisms in CAR-NK cell therapy","volume":"13","author":"Valeri","year":"2022","journal-title":"Front Immunol"},{"key":"2024122016182282300_bib143","doi-asserted-by":"publisher","first-page":"10961","DOI":"10.1073\/pnas.1005641107","article-title":"Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity","volume":"107","author":"Cella","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024122016182282300_bib144","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/35040504","article-title":"Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function","volume":"408","author":"Parrish-Novak","year":"2000","journal-title":"Nature"},{"key":"2024122016182282300_bib145","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s00268-009-0142-z","article-title":"Comparative study on overexpression of HER2\/neu and HER3 in gastric cancer","volume":"33","author":"Zhang","year":"2009","journal-title":"World J Surg"},{"key":"2024122016182282300_bib146","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jso.10222","article-title":"Role of MUC1 and MUC5AC expressions as prognostic indicators in gastric carcinomas","volume":"83","author":"Wang","year":"2003","journal-title":"J Surg Oncol"},{"key":"2024122016182282300_bib147","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/1096-9098(200007)74:3<185::AID-JSO4>3.0.CO;2-0","article-title":"Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients","volume":"74","author":"Kim","year":"2000","journal-title":"J Surg Oncol"},{"key":"2024122016182282300_bib148","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00535-016-1197-x","article-title":"Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility","volume":"51","author":"Shiraishi","year":"2016","journal-title":"J Gastroenterol"},{"key":"2024122016182282300_bib149","doi-asserted-by":"publisher","first-page":"102923","DOI":"10.1016\/j.redox.2023.102923","article-title":"Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation","volume":"67","author":"Yao","year":"2023","journal-title":"Redox Biol"},{"key":"2024122016182282300_bib150","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.bulcan.2019.03.012","article-title":"HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer","volume-title":"Bull Cancer","author":"Wu","year":"2019"},{"key":"2024122016182282300_bib151","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.bulcan.2019.03.012","article-title":"HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer","volume":"106","author":"Wu","year":"2019","journal-title":"Bull Cancer"},{"key":"2024122016182282300_bib152","doi-asserted-by":"publisher","first-page":"13364","DOI":"10.3390\/ijms241713364","article-title":"CAR-NK cells generated with mRNA-LNPs kill tumor target cells In vitro and In vivo","volume":"24","author":"Golubovskaya","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2024122016182282300_bib153","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1538-7445.AM2024-1326","article-title":"Pre-clinical development of ARB011: A CDH17 targeting allogeneic nonviral RNA-based \u201cFlash\u201d CAR-NK therapy for gastrointestinal cancer","volume":"84","author":"Roy","year":"2024","journal-title":"Cancer Res"},{"key":"2024122016182282300_bib154","doi-asserted-by":"publisher","first-page":"886429","DOI":"10.3389\/fimmu.2022.886429","article-title":"Next generation natural killer cells for cancer immunotherapy","volume-title":"Front Immunol","author":"Rossi","year":"2022"},{"key":"2024122016182282300_bib155","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.3389\/fimmu.2019.03038","article-title":"Influence of the tumor microenvironment on NK cell function in solid tumors","volume":"10","author":"Melaiu","year":"2020","journal-title":"Front Immunol"},{"key":"2024122016182282300_bib156","doi-asserted-by":"publisher","first-page":"1081546","DOI":"10.3389\/fimmu.2022.1081546","article-title":"Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"2024122016182282300_bib157","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.it.2020.12.001","article-title":"Monocyte regulation in homeostasis and malignancy","volume":"42","author":"Robinson","year":"2021","journal-title":"Trends Immunol"},{"key":"2024122016182282300_bib158","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab"},{"key":"2024122016182282300_bib159","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s40425-019-0610-4","article-title":"Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide","volume":"7","author":"Lee","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2024122016182282300_bib160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13046-022-02366-6","article-title":"A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces malignancy progression","volume":"41","author":"Piao","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2024122016182282300_bib161","doi-asserted-by":"publisher","first-page":"2338951","DOI":"10.1080\/2162402X.2024.2338951","article-title":"PD-L1(+) macrophages suppress T cell-mediated anticancer immunity","volume":"13","author":"Liu","year":"2024","journal-title":"Oncoimmunology"},{"key":"2024122016182282300_bib162","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/cas.16083","article-title":"Regulator of G protein signaling 1 is a potential target in gastric cancer and impacts tumor-associated macrophages","volume-title":"Cancer Sci","author":"Wu","year":"2024"},{"key":"2024122016182282300_bib163","doi-asserted-by":"publisher","first-page":"106828","DOI":"10.1016\/j.intimp.2020.106828","article-title":"BICC1 as a novel prognostic biomarker in gastric cancer correlating with immune infiltrates","volume":"87","author":"Zhao","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2024122016182282300_bib164","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.2147\/ott.S314561","article-title":"FSTL3 is a prognostic biomarker in gastric cancer and is correlated with M2 macrophage infiltration","volume":"14","author":"Liu","year":"2021","journal-title":"Onco Targets Ther"},{"key":"2024122016182282300_bib165","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12957-022-02830-9","article-title":"YKL-39 is an independent prognostic factor in gastric adenocarcinoma and is associated with tumor-associated macrophage infiltration and angiogenesis","volume":"20","author":"Xue","year":"2022","journal-title":"World J Surg Oncol"},{"key":"2024122016182282300_bib166","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.3390\/cells11223692","article-title":"CAR-macrophages and CAR-T cells synergistically kill tumor cells in vitro","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"2024122016182282300_bib167","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2024122016182282300_bib168","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"},{"key":"2024122016182282300_bib169","doi-asserted-by":"publisher","first-page":"1211687","DOI":"10.3389\/fbioe.2023.1211687","article-title":"Emerging advances in nanobiomaterials-assisted chimeric antigen receptor (CAR)-macrophages for tumor immunotherapy","volume":"11","author":"Zhang","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"2024122016182282300_bib170","doi-asserted-by":"publisher","first-page":"e36688","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"eLife"},{"key":"2024122016182282300_bib171","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat Immunol"},{"key":"2024122016182282300_bib172","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00705-022-05432-8","article-title":"Viruses as tools in gene therapy, vaccine development, and cancer treatment","volume":"167","author":"bin\u00a0Umair","year":"2022","journal-title":"Arch Virol"},{"key":"2024122016182282300_bib173","doi-asserted-by":"publisher","first-page":"e21886","DOI":"10.1016\/j.heliyon.2023.e21886","article-title":"Enhanced infection efficiency and cytotoxicity mediated by vpx-containing lentivirus in chimeric antigen receptor macrophage (CAR-M)","volume-title":"Heliyon","author":"Gao","year":"2023"},{"key":"2024122016182282300_bib174","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral vectors in gene therapy: recent development, challenges, and prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J"},{"key":"2024122016182282300_bib175","doi-asserted-by":"publisher","first-page":"783305","DOI":"10.3389\/fimmu.2021.783305","article-title":"Engineered CAR-macrophages as adoptive immunotherapies for solid tumors","volume-title":"Front Immunol","author":"Sloas","year":"2021"},{"key":"2024122016182282300_bib176","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1097\/CM9.0000000000002818","article-title":"Chimeric antigen receptor-immune cells against solid tumors: structures, mechanisms, recent advances, and future developments","volume":"137","author":"Li","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"2024122016182282300_bib177","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/cancers15051597","article-title":"The new frontier of immunotherapy: chimeric antigen receptor T (CAR-T) cell and macrophage (CAR-M) therapy against breast cancer","volume-title":"Cancers (Basel)","author":"Schepisi","year":"2023"},{"key":"2024122016182282300_bib178","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41416-023-02319-6","article-title":"Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer","volume":"129","author":"Dong","year":"2023","journal-title":"Br J Cancer"},{"key":"2024122016182282300_bib179","doi-asserted-by":"publisher","first-page":"e2103258","DOI":"10.1002\/adma.202103258","article-title":"Nanocomplex-mediated In vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy","volume":"33","author":"Kang","year":"2021","journal-title":"Adv Mater"},{"key":"2024122016182282300_bib180","doi-asserted-by":"publisher","first-page":"e002741","DOI":"10.1136\/jitc-2021-002741","article-title":"CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies","volume":"9","author":"Abdin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2024122016182282300_bib181","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/CM9.0000000000002919","article-title":"Immune cells in the B-cell lymphoma microenvironment: from basic research to clinical applications","volume":"137","author":"Zhang","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"2024122016182282300_bib182","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3389\/fonc.2019.01146","article-title":"Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy","volume":"9","author":"Masucci","year":"2019","journal-title":"Front Oncol"},{"key":"2024122016182282300_bib183","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.cell.2019.05.047","article-title":"Neutrophils driving unconventional T cells mediate resistance against Murine Sarcomas and selected Human tumors","volume":"178","author":"Ponzetta","year":"2019","journal-title":"Cell"},{"key":"2024122016182282300_bib184","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/jlb.4ri0418-151r","article-title":"The interplay between neutrophils and microbiota in cancer","volume":"104","author":"Smith","year":"2018","journal-title":"J Leukoc Biol"},{"key":"2024122016182282300_bib185","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/jlb.3a0120-050rr","article-title":"Melanoma-derived extracellular vesicles skew neutrophils into a pro-tumor phenotype","volume":"111","author":"Guimar\u00e3es-Bastos","year":"2022","journal-title":"J Leukoc Biol"},{"key":"2024122016182282300_bib186","doi-asserted-by":"publisher","first-page":"111605","DOI":"10.1016\/j.biopha.2021.111605","article-title":"CAR-macrophage: A new immunotherapy candidate against solid tumors","volume":"139","author":"Chen","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2024122016182282300_bib187","doi-asserted-by":"publisher","first-page":"111128","DOI":"10.1016\/j.celrep.2022.111128","article-title":"Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy","volume-title":"Cell Rep","author":"Chang","year":"2022"},{"key":"2024122016182282300_bib188","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.regen.2023.100074","article-title":"Engineered anti-prostate cancer CAR-neutrophils from human pluripotent stem cells","volume":"20","author":"Harris","year":"2023","journal-title":"J Immunol Regen Med"},{"key":"2024122016182282300_bib189","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","article-title":"CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy","volume":"14","author":"Chang","year":"2023","journal-title":"Nat Commun"},{"key":"2024122016182282300_bib190","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"2024122016182282300_bib191","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.3390\/diagnostics12092116","article-title":"Severe immune-related adverse events: A case series of patients needing hospital admission in a Spanish oncology referral center and review of the literature","volume":"12","author":"Segui","year":"2022","journal-title":"Diagnostics (MDPI, Basel, Switzerland.)"},{"key":"2024122016182282300_bib192","doi-asserted-by":"publisher","first-page":"102031","DOI":"10.1016\/j.clinre.2022.102031","article-title":"Comprehensive analysis of treatment-related adverse events of immunotherapy in advanced gastric or gastroesophageal junction cancer: A meta-analysis of randomized controlled trials","volume":"46","author":"Yuan","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2024122016182282300_bib193","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s00432-024-05703-8","article-title":"Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world","volume":"150","author":"Hao","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"2024122016182282300_bib194","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40425-019-0508-1","article-title":"Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial","volume":"7","author":"Chung","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2024122016182282300_bib195","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12885-020-06958-3","article-title":"Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric adenocarcinoma\u2014the randomized phase 2 INTEGA trial (AIO STO 0217)","volume-title":"BMC Cancer","author":"Tintelnot","year":"2020"},{"key":"2024122016182282300_bib196","doi-asserted-by":"publisher","first-page":"1748982","DOI":"10.1080\/2162402X.2020.1748982","article-title":"Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis","volume-title":"Oncoimmunology","author":"Shulgin","year":"2020"},{"key":"2024122016182282300_bib197","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"2024122016182282300_bib198","doi-asserted-by":"publisher","first-page":"109317","DOI":"10.1016\/j.intimp.2022.109317","article-title":"Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis","volume":"113","author":"Noori","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"2024122016182282300_bib199","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2020.10.030","article-title":"Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis","volume":"144","author":"Park","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024122016182282300_bib200","doi-asserted-by":"publisher","first-page":"734323","DOI":"10.3389\/fonc.2021.734323","article-title":"Comparison of efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol"},{"key":"2024122016182282300_bib201","doi-asserted-by":"publisher","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: A practical guide to identifying high-Risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"2024122016182282300_bib202","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12865-024-00599-y","article-title":"Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors","volume":"25","author":"Wang","year":"2024","journal-title":"BMC Immunol"},{"key":"2024122016182282300_bib203","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024122016182282300_bib204","doi-asserted-by":"publisher","first-page":"834113","DOI":"10.3389\/fphar.2022.834113","article-title":"Effectiveness and safety of anti-CD19 chimeric antigen receptor-T cell immunotherapy in patients with relapsed\/refractory large B-cell lymphoma: A systematic review and meta-analysis","volume":"13","author":"Ying","year":"2022","journal-title":"Front Pharmacol"},{"key":"2024122016182282300_bib205","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/mt.2015.60","article-title":"Case report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor","volume-title":"Mol Ther","author":"van\u00a0den\u00a0Berg","year":"2015"},{"key":"2024122016182282300_bib206","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/ajh.25445","article-title":"Toxicities of CD19 CAR-T cell immunotherapy","volume":"94","author":"Hirayama","year":"2019","journal-title":"Am J Hematol"},{"key":"2024122016182282300_bib207","doi-asserted-by":"publisher","first-page":"e8355","DOI":"10.7759\/cureus.8355","article-title":"Tumor Lysis Syndrome in solid tumors: A comprehensive literature review, new insights, and novel strategies to improve outcomes","volume-title":"Cureus","author":"Findakly","year":"2020"},{"key":"2024122016182282300_bib208","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2024122016182282300_bib209","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume-title":"Cancer Discov","author":"Santomasso","year":"2018"},{"key":"2024122016182282300_bib210","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"2024122016182282300_bib211","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/1078-0432.CCR-13-3017","article-title":"Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma","volume":"20","author":"Chodon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2024122016182282300_bib212","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jconrel.2015.09.069","article-title":"Shape and size-dependent immune response to antigen-carrying nanoparticles","volume":"220","author":"Kumar","year":"2015","journal-title":"J Control Release"},{"key":"2024122016182282300_bib213","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1039\/c6cs00636a","article-title":"Cellular uptake of nanoparticles: journey inside the cell","volume":"46","author":"Behzadi","year":"2017","journal-title":"Chem Soc Rev"},{"key":"2024122016182282300_bib214","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J Control Release"},{"key":"2024122016182282300_bib215","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat Nanotechnol"},{"key":"2024122016182282300_bib216","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jconrel.2016.01.044","article-title":"Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation","volume":"231","author":"Li","year":"2016","journal-title":"J Controlled Release"},{"key":"2024122016182282300_bib217","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.bioactmat.2020.12.010","article-title":"The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment","volume":"6","author":"Yang","year":"2021","journal-title":"Bioactive materials"},{"key":"2024122016182282300_bib218","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/17435390.2018.1472313","article-title":"Copper nanoparticles induce early fibrotic changes in the liver via TGF-\u03b2\/smad signaling and cause immunosuppressive effects in rats","volume":"12","author":"Lee","year":"2018","journal-title":"Nanotoxicology"},{"key":"2024122016182282300_bib219","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3389\/fbioe.2020.00627","article-title":"Cell membrane-based biomimetic nanoparticles and the immune system: immunomodulatory interactions to therapeutic applications","volume":"8","author":"Sushnitha","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"2024122016182282300_bib220","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.addr.2007.08.044","article-title":"Protein nanoparticles as drug carriers in clinical medicine","volume":"60","author":"Hawkins","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"2024122016182282300_bib221","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jconrel.2022.09.061","article-title":"Cancer stem cell antigen nanodisc cocktail elicits anti-tumor immune responses in melanoma","volume":"351","author":"Aikins","year":"2022","journal-title":"J Control Release"},{"key":"2024122016182282300_bib222","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat Mater"},{"key":"2024122016182282300_bib223","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.1038\/ncomms13193","article-title":"Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy","volume":"7","author":"Chen","year":"2016","journal-title":"Nat Commun"},{"key":"2024122016182282300_bib224","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1016\/j.vaccine.2014.09.002","article-title":"High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine","volume-title":"Vaccine","author":"Saito","year":"2014"},{"key":"2024122016182282300_bib225","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-08-2227","article-title":"Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer","volume":"15","author":"Speetjens","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2024122016182282300_bib226","doi-asserted-by":"publisher","first-page":"e12875","DOI":"10.1111\/sji.12875","article-title":"Development of tumour peptide vaccines: from universalization to personalization","volume":"91","author":"Ma","year":"2020","journal-title":"Scand J Immunol"},{"key":"2024122016182282300_bib227","doi-asserted-by":"publisher","first-page":"e2003757","DOI":"10.1002\/smll.202003757","article-title":"Potent-by-design: amino acids mimicking porous nanotherapeutics with intrinsic anticancer targeting properties","volume-title":"Small","author":"Wu","year":"2020"},{"key":"2024122016182282300_bib228","doi-asserted-by":"publisher","first-page":"115337","DOI":"10.1016\/j.biopha.2023.115337","article-title":"A state-of-art of underlying molecular mechanisms and pharmacological interventions\/nanotherapeutics for cisplatin resistance in gastric cancer","volume":"166","author":"Gupta","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2024122016182282300_bib229","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s00262-022-03355-6","article-title":"A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes","volume-title":"Cancer Immunol Immunother","author":"Li","year":"2023"}],"container-title":["Precision Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pcm\/advance-article-pdf\/doi\/10.1093\/pcmedi\/pbae020\/59192063\/pbae020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pcm\/article-pdf\/7\/4\/pbae020\/60784546\/pbae020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pcm\/article-pdf\/7\/4\/pbae020\/60784546\/pbae020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T16:18:46Z","timestamp":1734711526000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pcm\/article\/doi\/10.1093\/pcmedi\/pbae020\/7761075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":229,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10,11]]}},"URL":"https:\/\/doi.org\/10.1093\/pcmedi\/pbae020","relation":{},"ISSN":["2096-5303","2516-1571"],"issn-type":[{"value":"2096-5303","type":"print"},{"value":"2516-1571","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,9,19]]},"article-number":"pbae020"}}